ScholarIQanswers from OpenAlex & ORCID
Mark Raffeld
ResearcherPublications, citations & collaboration network
Mark Raffeld is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mark Raffeld have?
ScholarIQindexed works
Mark Raffeld has 795 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark Raffeld have?
ScholarIQcitation count
Mark Raffeld has 46,214 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mark Raffeld?
ScholarIQh-index
Mark Raffeld has an h-index of 113 in OpenAlex.
What is the i10-index of Mark Raffeld?
ScholarIQi10-index
Mark Raffeld has an i10-index of 384 in OpenAlex.
What is the ORCID of Mark Raffeld?
ScholarIQorcid
The ORCID for Mark Raffeld is on the source record.
What is the OpenAlex record for Mark Raffeld?
ScholarIQopenalex
The OpenAlex for Mark Raffeld is on the source record.
What are the most-cited papers on Mark Raffeld?
ScholarIQmost cited works
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins, James Chih‐Hsin Yang, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Richard M. Sherry, Nicholas P. Restifo, Amy M. Hubicki, Michael R. Robinson, Mark Raffeld, Paul H. Duray, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Sharon Mavroukakis, Donald E. White, Steven A. Rosenberg
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins, Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, John R. Wunderlich, Azam Nahvi, Lee J. Helman, Crystal L. Mackall, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Catherine Lévy, Yong F. Li, Mona El‐Gamil, Susan Schwarz, Carolyn M. Laurençot, Steven A. Rosenberg
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert Somerville, Robert O. Carpenter, Maryalice Stetler‐Stevenson, James C. Yang, Giao Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven A. Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, André Goy, Tatyana Feldman, David Spaner, Michael Wang, Clara C. Chen, Sarah M. Kranick, Avindra Nath, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, Steven A. Rosenberg
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler‐Stevenson, Steven A. Feldman, Irina Marić, Mark Raffeld, Debbie-Ann N. Nathan, Brock Lanier, Richard A. Morgan, Steven A. Rosenberg
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu, Patricia Pérez‐Galán, Delong Liu, Angélique Biancotto, Stefania Pittaluga, Bérengère Vire, Federica Gibellini, Ndegwa Njuguna, Elinor Lee, Lawrence Stennett, Nalini Raghavachari, Poching Liu, J. Philip McCoy, Mark Raffeld, Maryalice Stetler‐Stevenson, Constance M. Yuan, Richard M. Sherry, Diane C. Arthur, Irina Marić, Therese White, Gerald E. Marti, Peter J. Munson, Wyndham H. Wilson, Adrian Wiestner